AU730537B2 - Methods and compositions for transforming dendritic cells and activating T cells - Google Patents

Methods and compositions for transforming dendritic cells and activating T cells Download PDF

Info

Publication number
AU730537B2
AU730537B2 AU22660/97A AU2266097A AU730537B2 AU 730537 B2 AU730537 B2 AU 730537B2 AU 22660/97 A AU22660/97 A AU 22660/97A AU 2266097 A AU2266097 A AU 2266097A AU 730537 B2 AU730537 B2 AU 730537B2
Authority
AU
Australia
Prior art keywords
cell
cells
dendritic
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22660/97A
Other languages
English (en)
Other versions
AU2266097A (en
Inventor
Patrick Hwu
Mark Reeves
Steven A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of AU2266097A publication Critical patent/AU2266097A/en
Application granted granted Critical
Publication of AU730537B2 publication Critical patent/AU730537B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU22660/97A 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating T cells Ceased AU730537B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1143396P 1996-02-08 1996-02-08
US60/011433 1996-02-08
PCT/US1997/002063 WO1997029183A2 (en) 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating t cells

Publications (2)

Publication Number Publication Date
AU2266097A AU2266097A (en) 1997-08-28
AU730537B2 true AU730537B2 (en) 2001-03-08

Family

ID=21750351

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22660/97A Ceased AU730537B2 (en) 1996-02-08 1997-02-07 Methods and compositions for transforming dendritic cells and activating T cells

Country Status (7)

Country Link
EP (1) EP0879281B1 (enExample)
JP (1) JP2000505650A (enExample)
AT (1) ATE314462T1 (enExample)
AU (1) AU730537B2 (enExample)
CA (1) CA2245170A1 (enExample)
DE (1) DE69734974D1 (enExample)
WO (1) WO1997029183A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0840622A4 (en) * 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7351546B2 (en) 1998-09-22 2008-04-01 Becton, Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
US6495333B1 (en) 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay
AU3755800A (en) * 1999-03-15 2000-10-04 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
EP1046911A1 (en) * 1999-04-23 2000-10-25 Universiteit van Amsterdam Methods for identification of proteinaceous substances capable of inducing cellular reactions
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7767202B2 (en) * 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
FR2824567B1 (fr) 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
EP1450828B1 (en) 2001-08-17 2015-04-01 Roger Williams Hospital In situ immunization
US7955845B2 (en) 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2006249199A1 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US20110313229A1 (en) * 2008-07-24 2011-12-22 Kiminobu Sugaya Therapy Targeting Cancer Stem Cells
US9678061B2 (en) * 2010-08-06 2017-06-13 Ludwig-Maximilians-Universität München Identification of T cell target antigens
AU2013203832B2 (en) * 2012-03-13 2016-09-15 Celularity Inc. Modified erythrocyte precursor cells and uses thereof
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
WO1995034676A1 (en) * 1994-06-15 1995-12-21 Systemix, Inc. Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0631618A4 (en) * 1992-03-04 1995-09-27 Systemix Inc CULTIVATION OF HEMOPOETIC STEM CELLS AND THEIR GENETOLOGICAL PRODUCTION.
EP0563485A1 (en) * 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
EP0840622A4 (en) * 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
WO1995034676A1 (en) * 1994-06-15 1995-12-21 Systemix, Inc. Population of cells enriched for myeloid and/or lymphoid progenitors and methods of making and using

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALIJAGIC ET AL. EUR J IMMUNOL, 1995, 25(11):3100-7 *

Also Published As

Publication number Publication date
CA2245170A1 (en) 1997-08-14
AU2266097A (en) 1997-08-28
ATE314462T1 (de) 2006-01-15
JP2000505650A (ja) 2000-05-16
DE69734974D1 (de) 2006-02-02
WO1997029183A2 (en) 1997-08-14
WO1997029183A3 (en) 1997-12-18
EP0879281B1 (en) 2005-12-28
EP0879281A2 (en) 1998-11-25

Similar Documents

Publication Publication Date Title
US6734014B1 (en) Methods and compositions for transforming dendritic cells and activating T cells
AU730537B2 (en) Methods and compositions for transforming dendritic cells and activating T cells
US6479286B1 (en) Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells
Wittig et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial
Specht et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
Reeves et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
Szabolcs et al. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
JP2002529073A (ja) 三次元装置における造血前駆細胞からのリンパ様組織特異的細胞の生成
US6465251B1 (en) Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
Bello-Fernandez et al. Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions
Movassagh et al. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells
JP2002502599A (ja) 増殖され遺伝子的に修飾されたヒト造血幹細胞集団
Parajuli et al. Cytolysis of human dendritic cells by autologous lymphokine‐activated killer cells: participation of both T cells and NK cells in the killing
Roddie et al. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines
CN102046780A (zh) 转染的细胞的生产方法
Akiyama et al. Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells
JP2002506980A (ja) 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
EP0995802B1 (en) Method for the delivery of nucleic acids to cells in vitro or ex vivo
WO1999063050A2 (en) Method for preparation and in vivo administration of antigen presenting cell composition
WO1998021314A2 (en) Method of promoting b-cell proliferation and activation and of modulating the immune system
WO2000009665A1 (en) Engineered antigen-presenting cells expressing an array of antigens and uses thereof
WO2001032841A9 (en) Method of in vitro t cell differentiation of cd34+ progenitor cells
Segall et al. Monocyte/macrophages and dendritic cells
Nordon et al. Summary and Future Directions
AU2003220722A1 (en) Method for preparation and in vivo administration of antigen presenting cell composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)